Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
183.89
+8.06 (4.58%)
At close: Jul 1, 2026, 4:00 PM EDT
184.45
+0.56 (0.30%)
Pre-market: Jul 2, 2026, 4:19 AM EDT
Illumina Revenue
Illumina had revenue of $1.09B in the quarter ending March 29, 2026, with 4.80% growth. This brings the company's revenue in the last twelve months to $4.39B, up 1.29% year-over-year. In the year 2025, Illumina had annual revenue of $4.34B, down -0.66%.
Revenue (ttm)
$4.39B
Revenue Growth
+1.29%
P/S Ratio
6.33
Revenue / Employee
$435,813
Employees
10,080
Market Cap
27.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2025 | 4.34B | -29.00M | -0.66% |
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | 3.54B | 210.00M | 6.30% |
| Dec 30, 2018 | 3.33B | 581.00M | 21.11% |
| Dec 31, 2017 | 2.75B | 354.00M | 14.76% |
| Jan 1, 2017 | 2.40B | 178.00M | 8.02% |
| Jan 3, 2016 | 2.22B | 358.64M | 19.27% |
| Dec 28, 2014 | 1.86B | 440.18M | 30.97% |
| Dec 29, 2013 | 1.42B | 272.66M | 23.74% |
| Dec 30, 2012 | 1.15B | 92.98M | 8.81% |
| Jan 1, 2012 | 1.06B | 152.80M | 16.93% |
| Jan 2, 2011 | 902.74M | 236.42M | 35.48% |
| Jan 3, 2010 | 666.32M | 93.10M | 16.24% |
| Dec 28, 2008 | 573.23M | 206.43M | 56.28% |
| Dec 30, 2007 | 366.80M | 182.21M | 98.71% |
| Dec 31, 2006 | 184.59M | 111.09M | 151.13% |
| Jan 1, 2006 | 73.50M | 22.92M | 45.31% |
| Jan 2, 2005 | 50.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.63B |
| Labcorp Holdings | 14.14B |
| Quest Diagnostics | 11.28B |
| ICON Public Limited Company | 8.27B |
| Agilent Technologies | 7.23B |
| IDEXX Laboratories | 4.45B |
| Mettler-Toledo International | 4.09B |
| Waters | 3.77B |
ILMN News
- 22 hours ago - Illumina price target raised to $200 from $170 at Piper Sandler - TheFly
- 2 days ago - Illumina price target raised to $200 from $180 at Guggenheim - TheFly
- 3 days ago - Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip - Reuters
- 5 days ago - Illumina resumed with a Market Perform at Bernstein - TheFly
- 8 days ago - Illumina price target raised to $145 from $122 at Barclays - TheFly
- 8 days ago - Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors - PRNewsWire
- 14 days ago - The Healthcare M&A Wave - Forbes
- 21 days ago - JPMorgan upgrades Illumina to Overweight after favorable customer survey - TheFly